electroCore

electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company that focuses on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform. The company's core offering is the gammaCore device, a non-invasive, hand-held therapy that delivers mild electrical stimulation to the vagus nerve through the skin on the neck. This nVNS technology is designed to treat various medical conditions, including cluster headaches, migraines, and other primary headache disorders.

ElectroCore's gammaCore device is FDA-cleared in the US for adjunctive use in the preventive treatment of cluster headaches in adults, acute treatment of episodic cluster headache pain in adults, and acute and preventive treatment of migraines in adolescents and adults. The device is also CE-marked in the European Union for acute and prophylactic treatment of primary headaches, including migraines, cluster headaches, trigeminal autonomic cephalalgias, hemicrania continua, and medication overuse headaches in adults.

In addition to its medical devices, ElectroCore offers consumer product offerings utilizing nVNS to promote general well-being and human performance in the US and select overseas markets. The company has expanded its intellectual property portfolio with patents related to its nVNS technology, including devices and methods for remote therapy, patient monitoring, and medical devices for treating conditions.

In January 2022, ElectroCore launched a US telehealth portal and online store, allowing patients to complete telehealth consultations, obtain prescriptions, and purchase the gammaCore Sapphire device directly from the company's website. This direct-to-consumer strategy aims to provide broader access to the company's nVNS therapy.

As of March 2023, ElectroCore reported no direct exposure to the Silicon Valley Bank, Silvergate Bank, or Signature Bank, holding corporate cash accounts with large global money center banks.